Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam

Ceftazidime-avibactam and ceftolozane-tazobactam are new antimicrobials with activity against multidrug-resistant Pseudomonas aeruginosa. We present the first case of persistent P. aeruginosa bacteremia with in vitro resistance to these novel antimicrobials. A 68-year-old man with newly diagnosed fo...

Full description

Saved in:
Bibliographic Details
Main Authors: Louie Mar Gangcuangco, Patricia Clark, Cynthia Stewart, Goran Miljkovic, Zane K. Saul
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:Case Reports in Infectious Diseases
Online Access:http://dx.doi.org/10.1155/2016/1520404
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832553448612036608
author Louie Mar Gangcuangco
Patricia Clark
Cynthia Stewart
Goran Miljkovic
Zane K. Saul
author_facet Louie Mar Gangcuangco
Patricia Clark
Cynthia Stewart
Goran Miljkovic
Zane K. Saul
author_sort Louie Mar Gangcuangco
collection DOAJ
description Ceftazidime-avibactam and ceftolozane-tazobactam are new antimicrobials with activity against multidrug-resistant Pseudomonas aeruginosa. We present the first case of persistent P. aeruginosa bacteremia with in vitro resistance to these novel antimicrobials. A 68-year-old man with newly diagnosed follicular lymphoma was admitted to the medical intensive care unit for sepsis and right lower extremity cellulitis. The patient was placed empirically on vancomycin and piperacillin-tazobactam. Blood cultures from Day 1 of hospitalization grew P. aeruginosa susceptible to piperacillin-tazobactam and cefepime identified using VITEK 2 (Biomerieux, Lenexa, KS). Repeat blood cultures from Day 5 grew P. aeruginosa resistant to all cephalosporins, as well as to meropenem by Day 10. Susceptibility testing performed by measuring minimum inhibitory concentration by E-test (Biomerieux, Lenexa, KS) revealed that blood cultures from Day 10 were resistant to ceftazidime-avibactam and ceftolozane-tazobactam. The Verigene Blood Culture-Gram-Negative (BC-GN) microarray-based assay (Nanosphere, Inc., Northbrook, IL) was used to investigate underlying resistance mechanism in the P. aeruginosa isolate but CTX-M, KPC, NDM, VIM, IMP, and OXA gene were not detected. This case report highlights the well-documented phenomenon of antimicrobial resistance development in P. aeruginosa even during the course of appropriate antibiotic therapy. In the era of increasing multidrug-resistant organisms, routine susceptibility testing of P. aeruginosa to ceftazidime-avibactam and ceftolozane-tazobactam is warranted. Emerging resistance mechanisms to these novel antibiotics need to be further investigated.
format Article
id doaj-art-1f5141c2fc284203944b8f51c67f365b
institution Kabale University
issn 2090-6625
2090-6633
language English
publishDate 2016-01-01
publisher Wiley
record_format Article
series Case Reports in Infectious Diseases
spelling doaj-art-1f5141c2fc284203944b8f51c67f365b2025-02-03T05:53:56ZengWileyCase Reports in Infectious Diseases2090-66252090-66332016-01-01201610.1155/2016/15204041520404Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-AvibactamLouie Mar Gangcuangco0Patricia Clark1Cynthia Stewart2Goran Miljkovic3Zane K. Saul4Department of Internal Medicine, Yale New Haven Health-Bridgeport Hospital, Bridgeport, CT, USADepartment of Microbiology, Yale New Haven Health-Bridgeport Hospital, Bridgeport, CT, USADepartment of Microbiology, Yale New Haven Health-Bridgeport Hospital, Bridgeport, CT, USADepartment of Internal Medicine, Yale New Haven Health-Bridgeport Hospital, Bridgeport, CT, USADepartment of Internal Medicine, Yale New Haven Health-Bridgeport Hospital, Bridgeport, CT, USACeftazidime-avibactam and ceftolozane-tazobactam are new antimicrobials with activity against multidrug-resistant Pseudomonas aeruginosa. We present the first case of persistent P. aeruginosa bacteremia with in vitro resistance to these novel antimicrobials. A 68-year-old man with newly diagnosed follicular lymphoma was admitted to the medical intensive care unit for sepsis and right lower extremity cellulitis. The patient was placed empirically on vancomycin and piperacillin-tazobactam. Blood cultures from Day 1 of hospitalization grew P. aeruginosa susceptible to piperacillin-tazobactam and cefepime identified using VITEK 2 (Biomerieux, Lenexa, KS). Repeat blood cultures from Day 5 grew P. aeruginosa resistant to all cephalosporins, as well as to meropenem by Day 10. Susceptibility testing performed by measuring minimum inhibitory concentration by E-test (Biomerieux, Lenexa, KS) revealed that blood cultures from Day 10 were resistant to ceftazidime-avibactam and ceftolozane-tazobactam. The Verigene Blood Culture-Gram-Negative (BC-GN) microarray-based assay (Nanosphere, Inc., Northbrook, IL) was used to investigate underlying resistance mechanism in the P. aeruginosa isolate but CTX-M, KPC, NDM, VIM, IMP, and OXA gene were not detected. This case report highlights the well-documented phenomenon of antimicrobial resistance development in P. aeruginosa even during the course of appropriate antibiotic therapy. In the era of increasing multidrug-resistant organisms, routine susceptibility testing of P. aeruginosa to ceftazidime-avibactam and ceftolozane-tazobactam is warranted. Emerging resistance mechanisms to these novel antibiotics need to be further investigated.http://dx.doi.org/10.1155/2016/1520404
spellingShingle Louie Mar Gangcuangco
Patricia Clark
Cynthia Stewart
Goran Miljkovic
Zane K. Saul
Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam
Case Reports in Infectious Diseases
title Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam
title_full Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam
title_fullStr Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam
title_full_unstemmed Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam
title_short Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam
title_sort persistent bacteremia from pseudomonas aeruginosa with in vitro resistance to the novel antibiotics ceftolozane tazobactam and ceftazidime avibactam
url http://dx.doi.org/10.1155/2016/1520404
work_keys_str_mv AT louiemargangcuangco persistentbacteremiafrompseudomonasaeruginosawithinvitroresistancetothenovelantibioticsceftolozanetazobactamandceftazidimeavibactam
AT patriciaclark persistentbacteremiafrompseudomonasaeruginosawithinvitroresistancetothenovelantibioticsceftolozanetazobactamandceftazidimeavibactam
AT cynthiastewart persistentbacteremiafrompseudomonasaeruginosawithinvitroresistancetothenovelantibioticsceftolozanetazobactamandceftazidimeavibactam
AT goranmiljkovic persistentbacteremiafrompseudomonasaeruginosawithinvitroresistancetothenovelantibioticsceftolozanetazobactamandceftazidimeavibactam
AT zaneksaul persistentbacteremiafrompseudomonasaeruginosawithinvitroresistancetothenovelantibioticsceftolozanetazobactamandceftazidimeavibactam